How Could the 21st Century Cures Act Aid Innovation?

How Could the 21st Century Cures Act Aid Innovation?
There’s more to the 21st Century Cures Act, which passed the full House of Representatives with overwhelming bipartisan support, than $9 billion in new funding for the National Institutes of Health (NIH) to pick up the pace of medical research.

The legislation also includes a number of provisions that would speed up the Food and Drug Administration review process for new drugs and medical devices, including so-called high-risk devices. While the increased funding for NIH has met with near universal support, the FDA provisions have engendered criticism that the Senate will encounter when it takes up the legislation.

Among the provisions that would change the way the FDA reviews applications for drugs and biological agents are:

  • A patient-focused drug development approach that would require the FDA to consider patient experiences, such as case studies and testimonials, along with clinical trials in the new drug review process.
  • Mandate a framework for the use of biomarkers, along with other drug-development tools, and ease the process for applicants to obtain accelerated approval plans.
  • For agents designated for rare conditions, the FDA would have to consider data previously submitted for a different agent that uses the same or similar underlying approach.
  • Require a program to include clinical experience when considering a new indication for a previously approved agent.
  • Create a streamlined program to accept clinical data summaries in support of a new indication for agents for treatment of cancer or other diseases.
  • Compel manufacturers of investigational agents to make basic information on their expanded access policy available to the public.
  • Require expedited guidance to give drug sponsors clarity regarding adverse events patients experience in an expanded access program.
  • Create incentives for orphan drug extensions for limited populations, including extending exclusivity for six months for an agent that receives approval for a new rare-disease indication.

For device oversight, the law would make the following changes in the FDA process:

  • Provide priority review for breakthrough devices.
  • Allow the use of FDA-authorized third-party vendors to certify companies’ quality systems in the pre-market review process.
  • Allow sponsors to submit registry data, studies published in peer-reviewed journals and data collected in foreign countries with device applications.
  • Allow the FDA to grant humanitarian device exemption to diseases and conditions that affect up to 8,000 people in the United States.
  • Remove the limitation on the use of non-local, or central, institutional review boards in medical device trials.

As critics line up to challenge the FDA provisions in the Senate, Sen. Lamar Alexander (R-Tenn.), chair of the Senate Health, Education, Labor and Pensions Committee that will take up the bill, has made it clear that he thinks the medical innovation process in the United States has bogged down.

“America is home to the sharpest scientists and boldest researchers who are every day finding cutting-edge cures, treatments, and devices to help make sick people well or make life easier for the disabled,” Alexander said in a statement earlier this year when releasing a report titled Innovation for Healthier Americans. “The challenge is that our process for developing and reviewing these products is out-of-date and unable to match the pace of discovery, so American patients are waiting too long for relief.”

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

Eyenuk’s EyeArt AI System Showing Its Value

Eyenuk’s EyeArt AI System Showing Its Value

New J&J Vision CMO Steps onto a Very Large Stage

New J&J Vision CMO Steps onto a Very Large Stage

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

Covid-19 Impact on Healthcare Company Valuations & Financings

Covid-19 Impact on Healthcare Company Valuations & Financings

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

About The Author

Rich Kirkner

Richard Kirkner is an award-winning journalist and editorial consultant who has specialized in ophthalmology and eye care media for three decades. Based in Philadelphia, his work has been recognized with more than 40 awards for editorial excellence.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

NEW VIDEOS

PODCASTS